banda transcan 2 2016ul

Title: High resolution project on prognosis and CARE of cancer patients.


Project Coordinator:
Milena SANT (Italy) Fondazione IRCCS Istituto Nazionale dei Tumori, Milan


Project Partners:
Karin M. G. HAUSTERMANS (Belgium) University Hospitals Leuven, Leuven
Pascale GROSCLAUDE (France ) Francim: Réseau Français des registres de cancer, Toulouse
Alexander KATALINIC (Germany) Institute for Cancer Epidemiology e.V., University Lübeck Cancer Registry of Schleswig-Holstein, Lübeck
Magdalena BIELSKA-LASOTA (Poland) National Institute of Public Health ñ National Institute of Hygiene (NIPHñNIH), Warszawa
Maja PRIMIC ZAKELI (Slovenia) Institute of Oncology Ljubljana, Ljubljana
Maria-José SANCHEZ-PEREZ (Spain) Granada Cancer Registry, Escuela Andaluza de Salùd Publica. CIBERESP. Instituto de Investigacion Biosanitaria. Granada


Project Abstract:
Cancer survival inequalities documented by EUROCARE need to be explained by Population Based Cancer Registry (CR) High Resolution (HR) studies that capture innovation in cancer diagnosis and treatment and investigate whether co-morbidities influence outcome and treatments. Main Aim: Study influence of patterns of care and co-morbidities on clinical outcomes in breast (BC) and colorectal cancer (CC) patients diagnosed in 2011-14 in some EU areas. Specific aims: Investigate influence of co-morbidity on treatment choice, adhesion to clinical guidelines, relapse and disease-free survival and their association with BC and CC prognostic characteristics. Additional aim: CRs possibility to access biobanks in their areas will be piloted through the validation of a plasma derived microRNA signature. Design &Work Plan. Each CR will recruit a sample of 500 cases per tumour site, and will abstract information on stage, diagnostic exams, morphology and bio-molecular subtype, treatment, co-morbidity and follow-up, from clinical records (as with HR study protocol). Data will be centralized and multivariable survival analyses will be carried out. In addition, a plasma-based microRNA signature predictive of distant metastatization in early stage BC will be validated using biobanks in partners areas. The project will be coordinated by the Fondazione IRCCS Istituto Nazionale dei Tumori and organised in 4 WPs. The research consortium includes CRs with past experience in HR studies, 1 basic research and 2 clinical teams, epidemiologists, public health experts.

Publishable Summary:
Cancer survival inequalities documented by EUROCARE need to be explained by Population Based Cancer Registry (CR) High Resolution (HR) studies which capture innovation in cancer diagnosis and treatment, and investigate whether co-morbidities influence outcome and treatments.

The main aim of the project was to study the influence of patterns of care and co-morbidities on clinical outcomes in breast (BC) and colorectal cancer (CC) patients diagnosed in 2011-14 in a number of EU areas.

Aims: (i) the influence of co-morbidity on treatment choice, adhesion to clinical guidelines, relapse and disease-free survival and their association with BC and CC prognostic characteristics; (ii) the CRs possibility to access biobanks in their areas, piloted through the validation of a plasma derived microRNA signature. Each CR recruited a sample of 500 breast and/or colorectal cancer cases, and abstracted information on stage, diagnostic exams, morphology and bio-molecular subtype, treatment, co-morbidity and follow-up, from clinical records (as with HR study protocol). Data was centralized and multivariable survival analyses were carried out. In addition, a plasma-based microRNA signature predictive of distant metastatisation in early stage BC were validated using biobanks in partners areas. The project was coordinated by the Fondazione IRCCS Istituto Nazionale dei Tumori and organised in 4 WPs. The research consortium includes CRs with past experience in HR studies, 1 basic research and 2 clinical teams, epidemiologists, and public health experts.

 

(Project funded under JTC 2013)


TRANSCAN-2 News


The 3rd and final TRANSCAN-2 symposium on Tumour Heterogeneity was held in Milan on October 24th
The symposium included talks from the funded consortia of JTC2014, co-funded by the EU, an exciting discussion on the impact and added value of transnational collaborations on cancer research and a poster prize competition for young scientists.
The event was hosted by Regione Lombardia, Italy with the collaboration of Fondazione Regionale per la Ricerca Biomedica
 
For further information please contact: liron.ef@moh.gov.il

 

Newsletters

Newsletter 8, May 2019

Newsletter 7, October 2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, December 2017
Newsletter 3, September 2017
Newsletter 2, April 2017
Newsletter 1, December 2016

To subscribe to TRANSCAN-2 newsletter mailing list please send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 14 guests and no members online